John Lennon said that life is what happens when you’re busy making other plans. For DexCom Inc., that’s not a bad thing. Founded in 1999, DexCom tried, but failed, to develop a fully implantable glucose sensor that would last for at least a year and help patients with diabetes avoid the numerous daily finger-sticks required to measure their blood glucose. Along the way, however, it did succeed in gaining FDA approval for a sensor that enables continuous glucose monitoring (CGM) for seven days at a time, and that may be enough to revolutionize diabetes care.
CGM is a hot topic at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in the home (or the hospital) glucose readings at any hour...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?